Healthcare -
Biotechnology - NASDAQ - US
$ 0.746
-6.12 %
$ 1.51 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Revelation Biosciences, Inc.
| Current Assets | 6.57 M |
| Cash & Short-Term Investments | 6.5 M |
| Receivables | 0 |
| Other Current Assets | 66.7 K |
| Non-Current Assets | 56.3 K |
| Long-Term Investments | 0 |
| PP&E | 56.3 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 1.91 M |
| Accounts Payable | 784 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 1.13 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Revelation Biosciences, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 7.98 M |
| Operating Income | -7.98 M |
| Other Expenses | 7.06 M |
| Net Income | -15 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Revelation Biosciences, Inc.
| Net Income | -15 M |
| Depreciation & Amortization | 27.9 K |
| Capital Expenditures | -19.2 K |
| Stock-Based Compensation | 169 K |
| Change in Working Capital | -3.42 M |
| Others | -2.9 M |
| Free Cash Flow | -18.3 M |
Wall Street Analysts Price Targets
Revelation Biosciences, Inc.
REVB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
REVB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Revelation Biosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated.
businesswire.com
- 4 weeks ago
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. “The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, w.
businesswire.com
- 1 month ago
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in.
businesswire.com
- 1 month ago
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced a new target indication for Gemini for the prevention of infection in severe burn patients requiring hospitalization (the GEM-PBI program). The use of Gemini for the prevention of infection in severe burn patients, as well as the prevention of infection post-surgery (the GEM-PSI p.
businesswire.com
- 1 month ago
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1.
businesswire.com
- 3 months ago
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation's Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA. The fireside chat will be webcast live here and available on our Investors section of.
businesswire.com
- 3 months ago
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FD.
businesswire.com
- 3 months ago
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the first patient in the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of intravenous single ascending doses of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US-based, multi-site, placebo-controlled study will enro.
businesswire.com
- 3 months ago
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC (“Nasdaq”) formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing. On January 21, 2025, Revelation announced the commencement.
businesswire.com
- 4 months ago
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under.
businesswire.com
- 5 months ago
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that it has started its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US based multi-site placeb.
businesswire.com
- 5 months ago
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franc.
businesswire.com
- 5 months ago
8. Profile
Summary
Revelation Biosciences, Inc. REVB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.51 M
Dividend Yield
0.00%
Description
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Contact
4660 La Jolla Village Drive, San Diego, CA, 92122
https://www.revbiosciences.com
IPO
Date
Nov. 17, 2020
Employees
8
Officers
Mr. Chester Stanley Zygmont III
Chief Financial Officer & Corporate Secretary
Ms. Carol Odle
Senior Director of Clinical Projects
Ms. Sandra Vedrick
Vice President of Human Resources & Investor Relations
Mr. James M. Rolke
Chief Executive Officer & Director